

**TELO GENOMICS CORP.**  
**(the “Company”)**

**NOTICE OF CHANGE OF AUDITOR**

Pursuant to Section 4.11 of National Instrument 51-102 *Continuous Disclosure Obligations* (“**NI 51-102**”), the Company hereby gives notice, as follows:

1. Smythe LLP, Chartered Professional Accountants (the “**Former Auditor**”) has resigned as the Company’s auditor on its own initiative, effective as of December 14, 2022.
2. The board of directors of the Company has determined to appoint Crowe MacKay LLP, Chartered Professional Accountants (the “**Successor Auditor**”) as the Company’s auditor in place of the Former Auditor, effective as of December 14, 2022, and to propose the Successor Auditor for appointment as the auditor of the Company at its next annual general meeting.
3. The resignation of the Former Auditor and the appointment of the Successor Auditor have been approved by the Company’s board of directors.
4. There have been no reservations or modified opinions expressed in the audit reports of the former auditor, for their audits of the Company’s two most recently completed financial years or for any period subsequent to the most recently completed financial period for which an audit report was issued and preceding December 14, 2022.
5. There has not been a “reportable event” (as such term is defined in section 4.11(1) of NI 51-102), between the Company and the former auditor.

Dated this 14<sup>th</sup> day of December, 2022

**TELO GENOMICS CORP.**

“Christopher Ross”

Christopher Ross  
Chief Financial Officer